Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06424834 · ClinicalTrials.gov registry record · Phase 2

Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

A Phase 2 study of Angina Pectoris and Microvascular Angina, sponsored by Stanford University.

Recruiting
Registry status
Phase 2
Development phase
150
Enrollment target
1
Study location

NCT06424834: Recruiting Phase 2 study of Angina Pectoris and Microvascular Angina, sponsored by Stanford University.

NCT06424834 is a Phase 2 study of Angina Pectoris and Microvascular Angina that is actively recruiting participants, run by Stanford University. The registered enrollment target is 150 participants, below the 898-participant average among 9 other Angina Pectoris trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06424834, a Phase 2 study of Angina Pectoris and Microvascular Angina, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
Phase 2
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing. Participants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks. They will be asked to complete a series of questionnaires to evaluate their quality of life at the beginning and end of the study.

Primary Outcome

Change in Seattle Angina Questionnaire summary score at follow-up compared to baseline. The score ranges from 0 - 100, with a higher score indicating a better outcome.

Interventions

  • DRUG Placebo
  • DRUG Amlodipine
  • DRUG Nebivolol

Study Locations (1)

California

  • Stanford Hospital - Palo Alto

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-10-10
Est. Completion 2026-12
Phase Phase 2
Stanford University

1,744 total trials

What NCT06424834 shows while recruiting

NCT06424834 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 898-participant average among 9 other Angina Pectoris trials with a reported enrollment target (83% lower).

The record links to 4 conditions, with Angina Pectoris appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06424834 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06424834 about?

NCT06424834 is a clinical study titled "Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries". The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing. Partic...

What is the current status of trial NCT06424834?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-10-10. Estimated completion is 2026-12.

What conditions does trial NCT06424834 study?

This clinical trial studies the following conditions: Angina Pectoris, Microvascular Angina, Vasospastic Angina, Myocardial Bridge of Coronary Artery.

What interventions are being tested in trial NCT06424834?

The interventions under investigation include: Placebo (DRUG), Amlodipine (DRUG), Nebivolol (DRUG).

Who is sponsoring clinical trial NCT06424834?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06424834 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Angina Pectoris

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06424834's enrollment target sits among peer trials

150 9th of 9 higher than 1 of 9 other Angina Pectoris trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Angina Pectoris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06424834, the US trial registry maintained by the National Library of Medicine. NCT06424834 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.